Export Ready — 

Inibidores do SGLT-2

Bibliographic Details
Main Author: Silva-Cardoso, José
Publication Date: 2021
Other Authors: Andrade, Aurora, Brito, Dulce, Ferreira, Jorge, Fonseca, Cândida, Peres, Marisa, Franco, Fátima, Moura, Brenda
Format: Other
Language: por
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10362/120537
Summary: Funding Information: José Silva-Cardoso has received speaker and consultant fees, advisory board participation fees, or investigational grants from Abbott, AstraZeneca Pharmaceuticals, Bial, Boehringer Ingelheim, Menarini, Merck Serono, Merck Sharp & Dohme, Novartis, Orion, Pfizer, Sanofi, Servier, and Vifor Pharma. Aurora Andrade has received speaker or advisory boards fees from Novartis, AstraZeneca, Servier, Orion and Bial. Dulce Brito has received speaker and consultant fees or investigational grants from AstraZeneca Pharmaceuticals, Boehringer Ingelheim, Novartis, Orion, Pfizer, Roche Diagnostics, Sanofi, Servier, and Vifor Pharma. Jorge Ferreira has received speaker and consultant fees from Amgen, AstraZeneca, Boehringer-Ingelheim, Novartis. Cândida Fonseca has received speaker and consultant fees, or investigational grants, from AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim, Merck Serono, Novartis, Orion, Pfizer, Sanofi, Servier, and Vifor Pharma. Marisa Peres has received speaker or advisory board fees from AstraZeneca, Servier, and Novartis. Fátima Franco has received speaker or advisory board fees from Boehringer, AstraZeneca, Novartis and Servier. Brenda Moura has received speaker or advisory board fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Servier, Novartis, Vifor Pharma. Publisher Copyright: © 2021 Sociedade Portuguesa de Cardiologia Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
id RCAP_4f707762bcc2b1765e25dbde7142e615
oai_identifier_str oai:run.unl.pt:10362/120537
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Inibidores do SGLT-2SGLT-2 inhibitorsA step forward in the treatment of heart failure with reduced ejection fractionum passo em frente no tratamento da ICFErCanagliflozinCardiovascular mortalityDapagliflozinEmpagliflozinErtugliflozinHeart failureHeart failure hospitalizationSGLT-2 inhibitorsSotagliflozinType-2 diabetes mellitusCardiology and Cardiovascular MedicineSDG 3 - Good Health and Well-beingFunding Information: José Silva-Cardoso has received speaker and consultant fees, advisory board participation fees, or investigational grants from Abbott, AstraZeneca Pharmaceuticals, Bial, Boehringer Ingelheim, Menarini, Merck Serono, Merck Sharp & Dohme, Novartis, Orion, Pfizer, Sanofi, Servier, and Vifor Pharma. Aurora Andrade has received speaker or advisory boards fees from Novartis, AstraZeneca, Servier, Orion and Bial. Dulce Brito has received speaker and consultant fees or investigational grants from AstraZeneca Pharmaceuticals, Boehringer Ingelheim, Novartis, Orion, Pfizer, Roche Diagnostics, Sanofi, Servier, and Vifor Pharma. Jorge Ferreira has received speaker and consultant fees from Amgen, AstraZeneca, Boehringer-Ingelheim, Novartis. Cândida Fonseca has received speaker and consultant fees, or investigational grants, from AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim, Merck Serono, Novartis, Orion, Pfizer, Sanofi, Servier, and Vifor Pharma. Marisa Peres has received speaker or advisory board fees from AstraZeneca, Servier, and Novartis. Fátima Franco has received speaker or advisory board fees from Boehringer, AstraZeneca, Novartis and Servier. Brenda Moura has received speaker or advisory board fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Servier, Novartis, Vifor Pharma. Publisher Copyright: © 2021 Sociedade Portuguesa de Cardiologia Copyright: Copyright 2021 Elsevier B.V., All rights reserved.Heart failure (HF) is a major health problem with a significant impact on morbidity, mortality, quality of life and healthcare costs. Despite the positive impact of disease-modifying therapies developed over the last four decades, HF mortality and hospitalization remain high. We aim at reviewing the evidence supporting the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, as a novel strategy for HF with reduced ejection fraction (HFrEF) treatment. The consistent observation of a reduction in HF hospitalizations in type-2 diabetes cardiovascular safety trials EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58 and VERTIS raised the hypothesis that SGLT-2 inhibitors could have an impact in HF treatment. This hypothesis was first confirmed in 2019 with the DAPA-HF publication showing that dapagliflozin on top of optimized HFrEF therapy, reduced HF-hospitalizations and cardiovascular mortality. This was reinforced by the EMPEROR-Reduced publication in 2020 showing that empagliflozin on top of optimized HFrEF therapy, reduced HF-hospitalizations. Both studies established SGLT-2 inhibitors as a fourth pillar of HFrEF prognosis-modifying therapy, in addition to the gold standard triple neurohormonal modulation/blockade.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNSilva-Cardoso, JoséAndrade, AuroraBrito, DulceFerreira, JorgeFonseca, CândidaPeres, MarisaFranco, FátimaMoura, Brenda2021-07-05T22:18:07Z2021-092021-09-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/otherapplication/pdfhttp://hdl.handle.net/10362/120537por0870-2551PURE: 31941853https://doi.org/10.1016/j.repc.2021.02.010info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-22T17:54:24Zoai:run.unl.pt:10362/120537Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T17:25:20.060654Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Inibidores do SGLT-2
SGLT-2 inhibitorsA step forward in the treatment of heart failure with reduced ejection fraction
um passo em frente no tratamento da ICFEr
title Inibidores do SGLT-2
spellingShingle Inibidores do SGLT-2
Silva-Cardoso, José
Canagliflozin
Cardiovascular mortality
Dapagliflozin
Empagliflozin
Ertugliflozin
Heart failure
Heart failure hospitalization
SGLT-2 inhibitors
Sotagliflozin
Type-2 diabetes mellitus
Cardiology and Cardiovascular Medicine
SDG 3 - Good Health and Well-being
title_short Inibidores do SGLT-2
title_full Inibidores do SGLT-2
title_fullStr Inibidores do SGLT-2
title_full_unstemmed Inibidores do SGLT-2
title_sort Inibidores do SGLT-2
author Silva-Cardoso, José
author_facet Silva-Cardoso, José
Andrade, Aurora
Brito, Dulce
Ferreira, Jorge
Fonseca, Cândida
Peres, Marisa
Franco, Fátima
Moura, Brenda
author_role author
author2 Andrade, Aurora
Brito, Dulce
Ferreira, Jorge
Fonseca, Cândida
Peres, Marisa
Franco, Fátima
Moura, Brenda
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Silva-Cardoso, José
Andrade, Aurora
Brito, Dulce
Ferreira, Jorge
Fonseca, Cândida
Peres, Marisa
Franco, Fátima
Moura, Brenda
dc.subject.por.fl_str_mv Canagliflozin
Cardiovascular mortality
Dapagliflozin
Empagliflozin
Ertugliflozin
Heart failure
Heart failure hospitalization
SGLT-2 inhibitors
Sotagliflozin
Type-2 diabetes mellitus
Cardiology and Cardiovascular Medicine
SDG 3 - Good Health and Well-being
topic Canagliflozin
Cardiovascular mortality
Dapagliflozin
Empagliflozin
Ertugliflozin
Heart failure
Heart failure hospitalization
SGLT-2 inhibitors
Sotagliflozin
Type-2 diabetes mellitus
Cardiology and Cardiovascular Medicine
SDG 3 - Good Health and Well-being
description Funding Information: José Silva-Cardoso has received speaker and consultant fees, advisory board participation fees, or investigational grants from Abbott, AstraZeneca Pharmaceuticals, Bial, Boehringer Ingelheim, Menarini, Merck Serono, Merck Sharp & Dohme, Novartis, Orion, Pfizer, Sanofi, Servier, and Vifor Pharma. Aurora Andrade has received speaker or advisory boards fees from Novartis, AstraZeneca, Servier, Orion and Bial. Dulce Brito has received speaker and consultant fees or investigational grants from AstraZeneca Pharmaceuticals, Boehringer Ingelheim, Novartis, Orion, Pfizer, Roche Diagnostics, Sanofi, Servier, and Vifor Pharma. Jorge Ferreira has received speaker and consultant fees from Amgen, AstraZeneca, Boehringer-Ingelheim, Novartis. Cândida Fonseca has received speaker and consultant fees, or investigational grants, from AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim, Merck Serono, Novartis, Orion, Pfizer, Sanofi, Servier, and Vifor Pharma. Marisa Peres has received speaker or advisory board fees from AstraZeneca, Servier, and Novartis. Fátima Franco has received speaker or advisory board fees from Boehringer, AstraZeneca, Novartis and Servier. Brenda Moura has received speaker or advisory board fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Servier, Novartis, Vifor Pharma. Publisher Copyright: © 2021 Sociedade Portuguesa de Cardiologia Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
publishDate 2021
dc.date.none.fl_str_mv 2021-07-05T22:18:07Z
2021-09
2021-09-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/other
format other
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/120537
url http://hdl.handle.net/10362/120537
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv 0870-2551
PURE: 31941853
https://doi.org/10.1016/j.repc.2021.02.010
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833596684461932544

Similar Items